Premium
Does a rise in the BCR‐ABL1 transcript level identify chronic phase CML patients responding to imatinib who have a high risk of cytogenetic relapse?
Author(s) -
Marin David,
Khorashad Jamshid S.,
Foroni Letizia,
Milojkovic Dragana,
Szydlo Richard,
Reid Alistair G.,
Rezvani Katayoun,
Bua Marco,
Goldman John M.,
Apperley Jane F.
Publication year - 2009
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.2009.07646.x
Subject(s) - imatinib , medicine , myeloid leukemia , oncology , abl , cancer research , tyrosine kinase , receptor
Summary BCR‐ABL1 transcript numbers were monitored in 161 patients who started treatment with imatinib early after diagnosis of chronic myeloid leukaemia in chronic phase and achieved complete cytogenetic responses (CCyR). A confirmed doubling in BCR‐ABL1 / ABL1 transcript levels was found to be a significant factor for predicting loss of CCyR [relative risk (RR) 8·3, P < 0·0001] and progression to advanced phase (RR 0·07, P = 0·03) provided that the eventual BCR‐ABL1 / ABL1 transcript level exceeded 0·05%; increases that never exceeded 0·05% had no predictive value. The finding of a kinase domain mutation in a patient in CCyR, though rare, also predicted for loss of CCyR.